Search
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "co...
Ergometrine
go.drugbank.com/drugs/DB01253ApprovedInvestigationalAn ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Amobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigationalVericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate t...
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigational[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597].
Etamicastat
go.drugbank.com/drugs/DB15288InvestigationalEtamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed pur...
Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigational[A1489,A1490] Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.[A1492]
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inop...